These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27159996)

  • 1. NICE recommends PCSK9 inhibitors for patients not responding to statins.
    Mayor S
    BMJ; 2016 May; 353():i2609. PubMed ID: 27159996
    [No Abstract]   [Full Text] [Related]  

  • 2. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
    Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
    [No Abstract]   [Full Text] [Related]  

  • 3. [Modern Lipid therapy today and tomorrow: anti-PCSK9 : A magic bullet concept following Paul Ehrlich].
    Erbel R; Gitt AK
    Herz; 2016 Jun; 41(4):271-2. PubMed ID: 27241696
    [No Abstract]   [Full Text] [Related]  

  • 4. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the role of PCSK9 inhibitors in treating hypercholesterolemia?
    Volpe M
    JAAPA; 2018 Jun; 31(6):14-15. PubMed ID: 29846311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiovascular Safety of Evolocumab: a Systematic Review and Meta-Analysis.
    Krittanawong C; Kitai T; Zhang H; Sun T
    Cardiovasc Drugs Ther; 2016 Dec; 30(6):645-646. PubMed ID: 27830381
    [No Abstract]   [Full Text] [Related]  

  • 9. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
    Yoon CH; Watson K
    Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
    Vuorio A; Watts GF; Kovanen PT
    J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
    [No Abstract]   [Full Text] [Related]  

  • 13. [PCSK9 inhibitors reduces LDL cholesterol by 60 percent].
    Nilsson P; Wiklund O
    Lakartidningen; 2017 Mar; 114():. PubMed ID: 28375534
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Hypercholesterolemia in 2015.
    Aronow WS
    Am J Ther; 2017; 24(2):e121-e129. PubMed ID: 26422823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The year in cardiology 2015: prevention.
    Chapman MJ; Blankenberg S; Landmesser U
    Eur Heart J; 2016 Feb; 37(6):510-9. PubMed ID: 26726043
    [No Abstract]   [Full Text] [Related]  

  • 16. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PCSK9 Inhibitors - the magic bullet for LDL cholesterol reduction?].
    Richter K; Barthel A; Bornstein SR; El-Armouche A; Wagner M
    Dtsch Med Wochenschr; 2016 Jun; 141(12):863-9. PubMed ID: 27305302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 Inhibitors: A Technology Worth Paying For?
    Weintraub WS; Gidding SS
    Pharmacoeconomics; 2016 Mar; 34(3):217-20. PubMed ID: 26689785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    Everett BM; Smith RJ; Hiatt WR
    N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation.
    Moayedi Y; Kozuszko S; Knowles JW; Chih S; Oro G; Lee R; Fearon WF; Ross HJ; Teuteberg JJ; Khush KK
    Can J Cardiol; 2019 Jan; 35(1):104.e1-104.e3. PubMed ID: 30595172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.